Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

Vitrolife Acquires into IVF diagnostics - ABG

Vitrolife

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Acquires IVF diagnostics company Igenomix
Pays 36x LTM EV/EBITDA
Pre-announced Q2’21 – CER sales growth of 94%

On Thursday 7 July, Vitrolife announced that it had entered into a agreement to acquire 100% of Igenomix from EQT and other shareholders. Igenomix was founded in 2011 and operates in women’s health and reproductive genetic testing for IVF clinics. The company has 26 labs globally, with US as its largest market. Tests offered include Endometrial Receptivity Analysis that evaluates the uterus and PGT-A for genetic evaluation of embryos. The company is headquartered in Valencia, Spain and has 560 employees. The acquisition will expand Vitrolife’s coverage of the IVF journey and it sees cross selling potential through Igenomix complementing IVF clinic service offering.

In conjunction with the acquisition Vitrolife also preannounced its Q2’21 figures. Sales came in at SEK 382m, corresponding CER growth of 94% (8% CER growth vs. Q2’19) and adj. EBITDA was SEK 148m for a margin of 39%. There is a conf. call at 10.00 CET. Dial-in: SEK: +46 8 566 184 67 INT: +44 2071 928338
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.